Top 50 Biotechnology Startup Investors in Norway (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Investinor
VC Fund
|
12 | Norway, United States, Sweden | Venture - Series Unknown, Series A | Software, Biotechnology, Manufacturing | $2M–$25M |
|
Birk Venture
VC Fund
|
5 | Norway, United Kingdom | Seed, Series A | Biotechnology, Medical, Health Care | $1.2M–$20M |
|
Hadean Ventures
VC Fund
|
4 | Sweden, Norway, Austria | Series A, Series B, Venture - Series Unknown | Biotechnology, Health Care, Medical | $2M–$79M |
|
Forbion Capital Partners
VC Fund
|
3 | United States, United Kingdom, The Netherlands | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $16M–$180M |
|
SINTEF Venture AS
VC Fund
|
3 | Norway, United States, United Kingdom | Seed, Venture - Series Unknown | Manufacturing, Information Technology, Software | $160k–$17M |
|
Sarsia Seed Management
VC Fund
|
2 | Norway | Venture - Series Unknown, Seed | Biotechnology, Software, Pharmaceutical | $1.5M–$3.9M |
|
Sandwater
VC Fund
|
2 | Norway, Germany, Finland | Series A, Venture - Series Unknown, Series B | Manufacturing, Medical, AgTech | $4.7M–$35M |
|
Canica
VC Fund
|
2 | Norway, Denmark, Singapore | Series A, Private Equity, Venture - Series Unknown | Biotechnology, Beauty, Retail | $2.1M–$29M |
|
Meneldor
VC Fund
|
2 | Norway, Germany, United Kingdom | Series A, Seed, Debt Financing | Biotechnology, Health Care, Pharmaceutical | $2.2M–$65M |
|
Sarsia
VC Fund
|
2 | Norway, Sweden, Finland | Seed, Pre-Seed, Venture - Series Unknown | Software, SaaS, Sensor | $625k–$8.8M |
|
Farvatn Venture
VC Fund
|
2 | Norway, United States, United Kingdom | Seed, Pre-Seed | Software, Artificial Intelligence, Health Care | $120k–$8M |
|
BIF Partners
VC Fund
|
2 | Germany, Israel, Norway | Seed, Convertible Note, Pre-Seed | Health Care, Biotechnology, Therapeutics | $1.3M–$2M |
|
M Ventures
VC Fund
|
2 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
EISMEA
VC Fund
|
2 | Spain, Italy, United Kingdom | Grant, Venture - Series Unknown, Seed | Manufacturing, Software, Biotechnology | $53k–$2.6M |
|
The Index Project
VC Fund
|
1 | United States, Denmark, Chile | Seed, Series A, Series B | Chemical, Artificial Intelligence, SaaS | $1.1M–$3M |
|
NantBio
VC Fund
|
1 | Norway | Seed | Life Science, Biotechnology | |
|
DNB
VC Fund
|
1 | Norway, Sweden, United States | Post-IPO Debt, Debt Financing, Venture - Series Unknown | Renewable Energy, Energy, Oil and Gas | $240k–$1.5B |
|
Faber
VC Fund
|
1 | Portugal, Germany, United Kingdom | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, SaaS | $121k–$25M |
|
Bakken & Baeck
VC Fund
|
1 | Norway | Seed, Angel | Chemical, Software, Life Science | |
|
PAACS Invest AS
VC Fund
|
1 | Norway | Seed | Consulting, Health Care, Biotechnology | |
|
Norselab
VC Fund
|
1 | Norway, Switzerland, United States | Seed, Venture - Series Unknown, Series A | Software, SaaS, Agriculture | $500k–$30M |
|
Advent Life Sciences
VC Fund
|
1 | United States, United Kingdom, France | Series A, Series B, Venture - Series Unknown | Biotechnology, Health Care, Medical | $5.5M–$104M |
|
CoFounder
VC Fund
|
1 | Norway | Seed, Series A | Industrial, Manufacturing, SaaS | $956k–$2.3M |
|
Fernando Lelo de Larrea H.
Angel
|
1 | Mexico, United States, Spain | Seed, Series A, Series B | E-Commerce, Financial Services, FinTech | $155k–$21M |
|
Sofinnova Partners
VC Fund
|
1 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7M–$105M |
|
Innovestor
VC Fund
|
1 | Finland, Sweden, Denmark | Seed, Pre-Seed | Software, Health Care, Information Technology | $204k–$4.5M |
|
Arkin Bio Ventures
VC Fund
|
1 | United States, Israel, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$182M |
|
Lekh Corp AS
VC Fund
|
1 | Norway | Pre-Seed | Software, Health Care, Life Science | |
|
Coalition for Epidemic Preparedness Innovations
VC Fund
|
1 | United States, India, United Kingdom | Grant, Post-IPO Equity, Seed | Biotechnology, Health Care, Pharmaceutical | $2.5M–$145M |
|
4BIO Capital
VC Fund
|
1 | United States, United Kingdom, France | Series A, Seed, Series B | Biotechnology, Health Care, Therapeutics | $5M–$125M |
|
Teknoinvest
VC Fund
|
1 | Sweden, Norway, United States | Series B, Series A | Health Care, Biotechnology, Medical | $1.2M–$31M |
|
TeleVenture Management
VC Fund
|
1 | Norway, United States | Venture - Series Unknown, Seed | Software, Manufacturing, Biotechnology | $686k–$5.9M |
|
Surveyor Capital
VC Fund
|
1 | United States, China, Canada | Series B, Post-IPO Equity, Series C | Biotechnology, Health Care, Therapeutics | $41M–$280M |
|
Bioqube Ventures
VC Fund
|
1 | United States, France, Norway | Seed, Series A, Series B | Biotechnology, Therapeutics, Life Science | $4M–$108M |
|
Innovations Kapital
VC Fund
|
1 | Sweden, Denmark, United States | Series B, Series C | Biotechnology, Health Care, Software | $5.5M–$30M |
|
ERM Invest
VC Fund
|
1 | Norway | Pre-Seed | Software, Health Care, Life Science | |
|
Norwegian Research Council
VC Fund
|
1 | Norway, Sweden | Grant, Seed, Venture - Series Unknown | Health Care, Biotechnology, Information Technology | $90k–$25M |
|
TD Veen
VC Fund
|
1 | Norway, United Kingdom, Germany | Seed, Venture - Series Unknown | Internet, Software, Information Technology | $913k–$19M |
|
Gezina
VC Fund
|
1 | Norway | Health Care, Biotechnology, Clinical Trials | ||
|
HealthCap
VC Fund
|
1 | United States, Sweden, France | Series B, Series A | Biotechnology, Health Care, Medical | $6M–$92M |
|
Qomel
VC Fund
|
1 | Norway | Seed | Life Science, Biotechnology | |
|
Dynamk Capital
VC Fund
|
1 | United States, Canada, Norway | Series A, Seed, Series B | Biotechnology, Medical, Health Care | |
|
Advent Venture Partners
VC Fund
|
1 | United Kingdom, United States, Switzerland | Series B, Series A | Biotechnology, Health Care, Software | $6.6M–$50M |
|
Nordic Impact
VC Fund
|
1 | Norway | Seed | Chemical, Life Science, Visual Search | |
|
Project Sandwater
VC Fund
|
1 | Norway, The Netherlands | Series A | Medical, Consulting, Life Science | $12M–$20M |
|
SR One
VC Fund
|
1 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6M–$175M |
|
H2O Holding AS
VC Fund
|
1 | Norway | Pre-Seed | Software, Health Care, Life Science | |
|
Patrick Pichette
Angel
|
1 | United Kingdom, Germany, United States | Seed, Series A, Series B | Artificial Intelligence, Software, Machine Learning | $913k–$95M |
|
World Wildlife Fund
VC Fund
|
1 | Canada, Norway, Faroe Islands | Seed, Series A | Seafood, Aquaculture, Food Processing | $1.5M–$6.2M |
|
Protonic Partners
VC Fund
|
1 | Norway | Seed | SaaS, Biometrics, Information Services | |
| Access all 152 investors in Norway Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Manufacturing
- Stage:Venture - Series Unknown, Series A
- Geography: Norway, United States, Sweden
Investor stats
- Total investments: 133
- Round size: Series A $2.3M–$25M; Venture - Series Unknown $2M–$19M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — raised $274M in 2011
Portfolio highlights
- Sonair — Sonair is building ADAR, the world's first safety-certified 3D sensor for human-robot collaboration. The commercial product is available now. Reach out for a demo.
- Two — Buy Now, Pay Later for your business customers. Two makes it easy and safe to offer invoice as a payment method on your e-commerce site.
- Muybridge — Reimagining cameras with weightless software-based viewpoint
Birk Venture is a Scandinavian venture company exclusively focusing on the life science industry.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A
- Geography: Norway, United Kingdom
Investor stats
- Total investments: 9
- Round size: Seed $1.3M–$15M; Series A $1.2M–$20M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- APIM Therapeutics — APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress.
- Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
- Accession Therapeutics — Accession Therapeutics is developing novel immuno-oncology therapeutics – combining high specificity and potency to counter tumor diversity. It is the first company to have engineered a viral point of entry to cancer cells while bypassing healthy cells - so it’s ‘gloves off’ in the fight against cancer." It was founded in 2020 and is locatedin Oxford, Oxfordshire, United Kingdom.
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across the region
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: Sweden, Norway, Austria
Investor stats
- Total investments: 36
- Round size: Series A $4.2M–$79M; Series B $4.5M–$75M; Venture - Series Unknown $2M–$29M
- Lead/follow: 50% lead, 50% follow
- Last fund: May invest from a new fund soon — raised $168M in 2021
Portfolio highlights
- Oncoinvent — Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of selected novel materials in new ways in order to maximize their medical benefit while minimizing potential safety concerns.
- Kasvu Therapeutics — Kasvu develops first and best-in-class small molecule neuroplastogens for diseases where neuronal connectivity is altered
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 229
- Round size: Series A $19M–$180M; Series B $16M–$155M; Series C $22M–$123M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely actively investing — fresh fund, raised $606M in 2026
Portfolio highlights
- OMass Therapeutics — OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
- Lisata Therapeutics — Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
We commercialize technology created by SINTEF's research environments
Show more...Investment focus
- Industry: Manufacturing, Information Technology, Software
- Stage:Seed, Venture - Series Unknown
- Geography: Norway, United States, United Kingdom
Investor stats
- Total investments: 34
- Round size: Seed $160k–$6.2M; Venture - Series Unknown $1.5M–$17M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $62M in 2018
Portfolio highlights
- Sonair — Sonair is building ADAR, the world's first safety-certified 3D sensor for human-robot collaboration. The commercial product is available now. Reach out for a demo.
- Hystar — Hystar develops polymer electrolyte membrane electrolyzers designed for large-scale green hydrogen production. Founded in 2020, Hystar's technology uses a unique cell design and process architecture that provides the ability to reduce electricity consumption and increase hydrogen output, enabling professionals to tackle various criticalenergy challenges and having the potential to reduce greenhouse gas emissions.
- Hydrogen Mem-Tech — Hydrogen Mem-Tech aim is to make the green shift happen through our state-of-the-art hydrogen separation technology with carbon capture.
Sarsia Seed AS is a Norwegian Seed Capital Fund which invests in Norwegian early phase technology companies within the energy/cleantech and biotechnology/life science sectors. The fund has a total capital of 333.5 million NOK (approx, 40 mEUR/50 mUSD) and is managed by Sarsia Seed Management AS. The management company advises the Fund board regarding investment decisions. The Fundâ€:tm:s duration is expected to be 12 (+3) years. The Management Teamâ€:tm:s strength lay in its competence, experience and extensive national and international network of industrial players and co-investors. The Teamâ€:tm:s collective experience comprises an optimal balance between operations, business and specialised technology know-how, applied research, and entrepreneurship; elements which are actively used both in the vetting and follow-up of investments.
Show more...Investment focus
- Industry: Biotechnology, Software, Pharmaceutical
- Stage:Venture - Series Unknown, Seed
- Geography: Norway
Investor stats
- Total investments: 11
- Round size: Venture - Series Unknown $1.5M–$3.9M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- BerGenBio — BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.
- Sonoclear — At SonoClear, we are dedicated to improving the diagnostic accuracy of ultrasound to give neurosurgeons the clarity needed to make critical decisions in the resection of tumours.
- Heimdall Power — Heimdall Power helps utilities optimize the power grid with state-of-the-art sensors and software, enabling real-time capacity management and situational awareness for a more efficient and reliable energy system.
We are Sandwater. Regeneration of our resources. Vitalizing healthcare & education. Improving life through technology.
Show more...Investment focus
- Industry: Manufacturing, Medical, AgTech
- Stage:Series A, Venture - Series Unknown, Series B
- Geography: Norway, Germany, Finland
Investor stats
- Total investments: 24
- Round size: Series A $8.5M–$24M; Series B $17M–$35M; Venture - Series Unknown $4.7M–$18M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Mantle8 — Using bottom-up exploration and decades of geology experience, we are on a mission to deliver natural hydrogen to the world.
- CurifyLabs — CurifyLabs enables 3D printed personalized medicines in pharmacies and hospitals. Always close to the patient.
- Alva Industries — Serving industries from aerospace to marine, we deliver high-performance, sustainable motors to drive a cleaner, more efficient future.
Canica is one of the largest privately owned investment companies in Norway. Our operations are focused on active, long-term ownership, primarily within sectors covering retail, fast moving consumer goods and real estate. Canica can offer core expertise within the fields of business development and finance, as well as capital and network in orderto create value and employment in a long-term perspective.
Show more...Investment focus
- Industry: Biotechnology, Beauty, Retail
- Stage:Series A, Private Equity, Venture - Series Unknown
- Geography: Norway, Denmark, Singapore
Investor stats
- Total investments: 16
- Round size: Series A $2.1M–$25M; Venture - Series Unknown $20M–$29M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Healthily — The path to perfect health starts with self-care and Healthily is here to guide you step by step.
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
- Oncoinvent — Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of selected novel materials in new ways in order to maximize their medical benefit while minimizing potential safety concerns.
Meneldor is a Dutch life-sciences investment firm backing exceptional science with disciplined VC capital to build and scale European biopharma with real impact.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Seed, Debt Financing
- Geography: Norway, Germany, United Kingdom
Investor stats
- Total investments: 8
- Round size: Series A $2.2M–$65M; Debt Financing $10M–$10M
- Lead/follow: 88% lead, 12% follow
Portfolio highlights
- Hemispherian — Hemispherian is an innovative preclinical pharmaceutical company focused on developing a novel class of small molecule drugs. These drugs target the TET2 enzyme as an epigenetic therapy for particularly aggressive cancers.
- Atriva Therapeutics — Therapies against viral infections. First-in-class host-targeting therapies to treat respiratory viral infections, including COVID-19 and influenza.
- Tagworks Pharmaceuticals — As pioneers of Click-to-Release technology, we are revolutionizing cancer treatment using in vivo click chemistry to increase the therapeutic window of powerful cancer therapies.
Sarsia is an early-stage venture capital investor that invest in science-based technology companies. It was founded in 2006 and is located in Bergen, Hordaland.
Show more...Investment focus
- Industry: Software, SaaS, Sensor
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: Norway, Sweden, Finland
Investor stats
- Total investments: 10
- Round size: Seed $2.1M–$2.7M; Pre-Seed $625k–$4.3M; Venture - Series Unknown $3.8M–$8.8M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Cetasol — Maritime monitoring and analytics software for commercial fleets. Full visibility, fuel savings, and compliance support.
- Birdsview — Sensor fusion of GPR radar, lidar and camera plus AI analysis: see inside any concrete structure without breaking it.
- Mitigrate — Mitigrate is building a SaaS platform to predict how physical climate risk will impact property assets in the future. The system provides businesses and asset owners with a cost-effective strategy to mitigate risk. The user gets connected to certified, local adaptation specialists who refine and implement the solution.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Planet 9 Venture supports startups and work with venture funds to make a positive imprint on the world.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Pre-Seed
- Geography: Norway, United States, United Kingdom
Investor stats
- Total investments: 85
- Round size: Seed $1M–$8M; Pre-Seed $120k–$1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Visoid — Render your 3D models with ease! Quick and easy rendering software for architects, powered by AI. Try Visoid for free!
- BioSort — Biometrics provides lice, biomass, extraction, and data analysis. They offer feed, fish health, welfare, optimized harvest aquaculture, and fisheries. They provide sensor technologies, machine vision, AI, software, mechatronics.
- Birdsview — Sensor fusion of GPR radar, lidar and camera plus AI analysis: see inside any concrete structure without breaking it.
Angel Investors focusing on Seed Investments
Show more...Investment focus
- Industry: Health Care, Biotechnology, Therapeutics
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: Germany, Israel, Norway
Investor stats
- Total investments: 14
- Round size: Seed $1.3M–$2M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Hemispherian — Hemispherian is an innovative preclinical pharmaceutical company focused on developing a novel class of small molecule drugs. These drugs target the TET2 enzyme as an epigenetic therapy for particularly aggressive cancers.
- ECO Group — Eco is a supplier of consumer products. They create structures for increased growth and profitability within the group companies.
- Lucid Genomics — Lucid Genomics is an AI-powered platform that focuses on diagnostics and biomarker detection. It offer comprehensive DNA analysis, that includes coding and non-coding mutation prioritization and interpretation.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 189
- Round size: Seed $2.4M–$24M; Series A $5.8M–$56M; Series B $13M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Mueon — semiconductor-based systems for AI and hyperscale computing
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.
EISMEA is an executive agency of the European Commission that implements European Union programs supporting innovation, small and medium-sized enterprises, and the Single Market. The agency manages the European Innovation Council and European Innovation Ecosystems programs under Horizon Europe. It also implements the SME component of the Single Market Programme and the Interregional Innovation Investments instrument. EISMEA provides funding and support for innovators, researchers, businesses, regions, and other organizations through grants, procurement, investment, and advisory programs. Its activities cover innovation development, SME competitiveness, entrepreneurship, market access, consumer policy, standardization, and interregional innovation. The agency also supports the implementation of EU policies and programs related to innovation ecosystems and economic development.
Show more...Investment focus
- Industry: Manufacturing, Software, Biotechnology
- Stage:Grant, Venture - Series Unknown, Seed
- Geography: Spain, Italy, United Kingdom
Investor stats
- Total investments: 3546
- Round size: Seed $53k–$800k; Grant $54k–$2M; Venture - Series Unknown $573k–$2.6M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- AGADE — Esoscheletri Agade | Il primo esoscheletro intelligente per lavoratori progettato per ridurre il rischio di disturbi muscolari delle spalle nella movimentazione manuale dei carichi.
- BroadBit Batteries — BroadBit is a technology company developing revolutionary new batteries using novel sodium-based chemistries to power the future green economy.
- Aenitis Technologies — We develop innovative devices for cells therapy processing using Acoustic Radiation Forces.
Design to improve life is about solving real problems, small and large, simple and complex, systemic and emerging and is a life-long pursuit. The Index Project is a call to action. Are you in?
Show more...Investment focus
- Industry: Chemical, Artificial Intelligence, SaaS
- Stage:Seed, Series A, Series B
- Geography: United States, Denmark, Chile
Investor stats
- Total investments: 9
- Round size: Seed $1.5M–$2M; Series A $1.1M–$3M
- Lead/follow: 0% lead, 100% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Agribuddy — Management of agricultural support application "AGRIBUDDY".
- CanopyLAB — CanopyLAB is an educational technology company located in Hvidovre, Greater Copenhagen, Denmark. We have built an AI-powered social learning platform for corporate training. Through personalization our platform enables all learners to realize their potential in a way that is fast, fun and future-proof. We call it "The Future of Learning-Delivered Today".We work on two verticals:1. The Canopy A social learning platform powered by AI A research-based social learning platform for developing competencies through individualized and adaptive learning experiences. It is designed with an integrated social network structure to enhance collaborative learning and built on strong Nordic learning principles.2. The LAB A learning community with provocative content Join our global learning community for youth. Take free courses, exchange ideas, gain new knowledge and practice competencies offered by 100 + pioneering NGOs in controversial and often neglected topics such as sexuality, sexual & reproductive rights, climate action, health, and the SDGs.CanopyLAB acquired Peruvian publishing startup Yopublico in April 2020.
- Destácame — Destacame is the first behavior-based credit score in Latin America.
NantBio offers treatments by developing molecularly targeted drugs, based on the molecular profile of the patient’s tumor.
Show more...Investment focus
- Industry: Life Science, Biotechnology
- Stage:Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Kure Cells — Kure Cells delivers innovative solutions in cell therapy, biotechnology, and clinical research to advance modern healthcare.
DNB is a financial services group that offers financial services through mobile, online banking, bank offices, and international offices. The Group provides a full range of financial services, including loans, savings, advisory services, insurance, and pension products for retail and corporate customers. The company’s personal banking products and services include savings and investment products. DNB offers its products and services to various sectors, including financial institutions, energy, manufacturing, healthcare, packaging, and forest products, shipping, offshore, and logistics, seafood, and telecom, media, and technology. They also distribute its products and services through its branches, in-store postal and banking outlets, and post office counters. DNB was founded in 1822 and is headquartered in Oslo, Norway.
Show more...Investment focus
- Industry: Renewable Energy, Energy, Oil and Gas
- Stage:Post-IPO Debt, Debt Financing, Venture - Series Unknown
- Geography: Norway, Sweden, United States
Investor stats
- Total investments: 55
- Round size: Post-IPO Debt $8.8M–$786M; Debt Financing $94M–$1.5B; Venture - Series Unknown $240k–$100M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Cadeler — Cadeler is an offshore services company that provides offshore wind installation and maintenance services. The company operates specialized vessels for transporting, installing, and servicing wind turbines and foundations in offshore environments, supporting the development of renewable energy infrastructure.
- Ventura Offshore — Ventura Offshore is an oil and gas services company that specialises in drilling, project management, offshore services, and asset management within the oil and gas industry. The company ensures efficient and safe operations in challenging offshore environments. By delivering innovative solutions and maintaining the highest standards of quality andsafety, Ventura Offshore supports the energy sector in maximising productivity and resource management.
- Clearway Energy Group — We're a leading independent clean power developer and operator with over 350 clean energy projects across America.
Faber is a Lisbon-based venture capital firm investing in outstanding entrepreneurs who innovate at the intersection of science and technology to drive digital transformation and climate action. The firm combines a specialist focus on deep tech early-stage startups with dedicated funds, investment teams and expert advisors to actively help founders build global companies powered by AI/Data, Web3 or Ocean/Climate technologies. Faber’s unique approach in Southern Europe is led by an entrepreneurial management partnership and backed by notable thesis-driven institutions and private investors. Investing since 2013, the firm has been an early investor in hard tech companies such as Unbabel, SWORD Health, Codacy, iLoF or YData.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Pre-Seed, Series A
- Geography: Portugal, Germany, United Kingdom
Investor stats
- Total investments: 100
- Round size: Seed $595k–$5.2M; Pre-Seed $121k–$3M; Series A $2.5M–$25M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely actively investing — fresh fund, raised $34M in 2024
Portfolio highlights
- Porelio — Porelio is an environmental technology that provides purification technologies for water and industrial chemicals.
- Helix Robotics — We are building the first commercial soft manipulator
- ATMOS Space Cargo — ATMOS Space Cargo develops and manufactures space capsules to return cargo from space, microgravity experiments, Commercial products to entire rocket stages.
Since 2011, we have built products with some of the most ambitious companies out there. From defining the future of conversational AI with Sierra to building decentralised platforms with Coinbase.
Show more...Investment focus
- Industry: Chemical, Software, Life Science
- Stage:Seed, Angel
- Geography: Norway
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Versor — Versor develops software necessary for true autonomous drone flight both indoors and outdoors, enabling complete automation of industrial drone operations. They believe this level of automation requires superior localization, which is particularly difficult to achieve indoors and in GPS-denied areas. By removing the need for pilots, entire fleetsof drones may be supervised remotely, enabling true scalability of drone operations across various applications.
- Iris.ai — Powerful Tools for Your Research. We have built a world-leading AI engine for scientific text understanding. Applied to literature reviews, data extraction, post-market surveillance or any other task involving thousands of documents like papers or patents, this engine will make your life a whole lot easier.
PAACS Invest is a privately owned Norwegian investment firm that focuses on active investments in healthcare and technology with a focus on sustainability.
Show more...Investment focus
- Industry: Consulting, Health Care, Biotechnology
- Stage:Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Hemispherian — Hemispherian is an innovative preclinical pharmaceutical company focused on developing a novel class of small molecule drugs. These drugs target the TET2 enzyme as an epigenetic therapy for particularly aggressive cancers.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!A startup studio situated in Oslo, built on and around the mobile and web development agency Norse Digital. Over the last few years, Norselab has created a strong portfolio of technology ventures built by the company's internal, world-class technology teams.
Show more...Investment focus
- Industry: Software, SaaS, Agriculture
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Norway, Switzerland, United States
Investor stats
- Total investments: 21
- Round size: Seed $500k–$6.3M; Series A $2.1M–$15M; Venture - Series Unknown $2.2M–$30M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Looping — Looping offers reuse as a service by substituting reusable transport packaging for single-use plastic products. It produces long-lasting and reusable transport wrapping for building modules, housing modules, and steel containers.
- Beefutures — Rooted in the beekeeping legacy and driven by expert engineering, Beefutures delivers accessible nature-based solutions to power a more sustainable world.
- Wanda — Wanda.space is a technology and logistics start-up delivering space as a service.
Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences, principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 73
- Round size: Series A $5.5M–$51M; Series B $21M–$97M; Venture - Series Unknown $7M–$104M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- Cyted — Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use AI and novel biomarkers to improve patient outcomes.
- Glycomine — We are developing a PMM2-CDG substrate replacement therapy. GLM101 is a mannose-1 phosphate treatment.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
CoFounder is a management and investment company for technology companies with great growth potential. They are experienced entrepreneurs and business developers who provide management resources and early-stage capital. They work with spin-offs from both research and industrial environments, as well as standalone entrepreneurial companies.
Show more...Investment focus
- Industry: Industrial, Manufacturing, SaaS
- Stage:Seed, Series A
- Geography: Norway
Investor stats
- Total investments: 10
- Round size: Seed $956k–$2.3M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- AlumatIQ — AlumatIQ specializes in industrial robotics, automation, and digitalization in the aluminum industry. Their first product is robotic automation of the anode change process, with high accuracy, consistency, and speed. Improves health and safety conditions for operators in pot rooms and reduces emissions of HF and greenhouse gases.
- Aviant — Delivering full-stack drone services that enables autonomous and on-demand transport of cargo.
- Receipts — Receipts is a single set of APIs that connects cashier systems and banks, allowing for digital receipts, card identification, and retail value-added services.
As a relevant player in Mexico’s entrepreneurial ecosystem, Fernando is one of the most important and active early-stage investors in Mexico. He has extensive experience in operational and financial aspects of private equity, project finance, and managing growing businesses. He heads Rumbo Ventures, the leading climate tech fund for Latin America.Fernando co-founded ALLVP in 2012 and has since invested in over 24 service-oriented companies in sectors such as healthcare, financial services, mobility, and e-commerce. Additionally, he co-founded NUMA México (formerly Venture Institute), the leading startup accelerator platform, and Fondeadora, LATAM´s pioneer crowdfunding platform that was sold to Kickstarter in 2016.After his tenure as COO and CFO of Umbral Capital, Fernando became CEO of the real estate private equity fund where he was responsible for managing USD$ 50M in capital commitments, and continued as Chairman of the Board after founding ALLVP. Before Umbral Capital, Fernando was Deputy Director of the Division of Energy and Project Finance in Protego Asesores, now Evercore Partners.Fernando holds an MBA from Stanford GSB, an MA in Economics from London School of Economics, and a BA in Economics from ITAM. Fernando has been active in Alternative Assets for more than 20 years, the last ten as founding partner of ALLVP.
Show more...Investment focus
- Industry: E-Commerce, Financial Services, FinTech
- Stage:Seed, Series A, Series B
- Geography: Mexico, United States, Spain
Investor stats
- Total investments: 34
- Round size: Seed $155k–$1.5M; Series A $330k–$7.4M; Series B $4.7M–$21M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- CoreZero — Turning less into more
- Thalasso — BLUE ECONOMY SARGASSUM MANAGEMENT
- TRIBBU — Hoop Carpool is a SaaS Carpooling Platform for Companies, Universities and Citi-halls
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 353
- Round size: Series A $7M–$70M; Series B $10M–$105M; Series C $12M–$100M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fresh fund, raised $755M in 2025
Portfolio highlights
- Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
- HighLife — HighLife is driven by a mission to deliver innovative treatment options to patients suffering from heart valve diseases.
- EnginZyme — Enzymatic chemistry for cleaner ingredients in personal care, food and pharma. Enginzyme's patented EziG platform makes enzymes work at industrial scale.
Innovestor is an active Finnish investment manager, focusing on venture capital, real estate, and energy storage. We also offer corporate venturing services.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Pre-Seed
- Geography: Finland, Sweden, Denmark
Investor stats
- Total investments: 87
- Round size: Seed $478k–$4.5M; Pre-Seed $204k–$2M
- Lead/follow: 59% lead, 41% follow
- Last fund: May invest from a new fund soon — raised $35M in 2020
Portfolio highlights
- Jaakko.com — Reinventing the housing market with no agents, more homes, and less fees.
- Retailgrid — Retailgrid is an AI-powered retail workspace that enables pricing, merchandising, and commercial teams to analyze data, run simulations, and make decisions in real time. Combining a flexible spreadsheet-like interface with AI agents, RetailGrid replaces fragmented tools and manual workflows with a single system for pricing optimization, promotionplanning, and assortment decisions. The platform connects to product, sales, and competitor data, automatically generates insights, and allows teams to test scenarios and deploy decisions at scale. RetailGrid is built for data-driven retailers looking to move faster and operate with the efficiency of top-tier consulting, without the cost or complexity.
- Bahn Express — Bahn Express is a global car transportation company that supports independent contractors while offering quick and easy auto shipping throughout Europe.
Explore Arkin Capital: A leading multi-asset manager driving strategic investments across health, technology, equity, real estate and more
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, Canada
Investor stats
- Total investments: 24
- Round size: Series A $11M–$125M; Series B $13M–$80M; Series C $19M–$182M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- Ambros Therapeutics — Ambros Therapeutics is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases.
- Reunion Neuroscience — Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.
Investment Company
Show more...Investment focus
- Industry: Software, Health Care, Life Science
- Stage:Pre-Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Aurora Analytica — Seven core decision engines and an orchestration layer working as one operating system for clinical development, from protocol optimization to study execution.
CEPI is a global partnership working to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Grant, Post-IPO Equity, Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 42
- Round size: Grant $3.2M–$42M; Post-IPO Equity $2.5M–$145M
- Lead/follow: 95% lead, 5% follow
Portfolio highlights
- Hilleman Laboratories — Hilleman Laboratories a medical research organization is committed to developing high impact, affordable vaccines for people in the developing countries in an innovative and sustainable manner.
- Minapharm Pharmaceuticals — MINAPHARM is constantly striving to provide innovative quality medicines and services to patients in developing countries so they, too, can get a timely benefit from the latest advances in pharmaceutical and biopharmaceutical research technologies. To achieve its mission and strategic goals, MINAPHARM exploits a robust research and developmentplatform combined with strategic multi-alliances involving industry players at the forefront of the latest pharmaceutical technologies, marketing and management techniques. This way has further enabled the establishment of specialized lines, embracing innovative and affordable products and services in the fields of Gastroenterology, Cardiology, Ophthalmology, Orthopedics, and Uro-gynaecology.
- Serum Institute of India Pvt. Ltd. — Serum Institute of India Pvt. Ltd. is the vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. It is estimated that about 65% of the children in the world receive at leastone vaccine manufactured by Serum Institute. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization, Geneva and are being used in around 140 countries across the globe in their national immunization programs, saving millions of lives throughout the world.
4BIO Ventures is a London-based firm investing in venture capital and public equities in life sciences. They are focused on advanced therapies addressing high unmet medical and social needs.4BIO Capital Partners is an emerging asset manager focusing on private equity and venture capital in high growth and high return segments of biotech -biologics, gene and cell therapy and bioinformatics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 32
- Round size: Seed $5M–$19M; Series A $24M–$94M; Series B $12M–$125M
- Lead/follow: 44% lead, 56% follow
- Last fund: May invest from a new fund soon — raised $50M in 2019
Portfolio highlights
- SparingVision — We are a genomic medicines company leading a step shift in how ocular diseases are treated. We are going beyond single gene correction therapies to deliver new treatments as quickly as possible to patients affected by Inherited Retinal Diseases (IRDs), regardless of genetic cause.
- March Biosciences — Transforming Patient Care by Unlocking New Target Spaces march.biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity of
- Cytospire Therapeutics — Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VC´s in Scandinavia according to track record of value created for their investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A
- Geography: Sweden, Norway, United States
Investor stats
- Total investments: 25
- Round size: Series A $1.2M–$12M; Series B $6M–$31M
- Lead/follow: 8% lead, 92% follow
- Last fund: May invest from a new fund soon — raised $53M in 2002
Portfolio highlights
- GLO — glō is a venture-backed company focused on the development and commercialization of advanced LED display products using nanotechnology. The unique nanotechnology is based on 11 years of research at Lund University’s Nanometer Structure Consortium. Headed by Professor Lars Samuelson, one of the world’s leading scientists in this field, who haspublished more than 500 papers related to this technology.glō's first office is in Lund, Sweden, where basic material research continues for the next generation nanotechnology. glō's research and product development along with pilot fabrication operation is carried out at glō-USA in Sunnyvale, California. In 2016, glō established an Asia office in Taipei, Taiwan, one of the largest and fastest-growing regions for LED lighting and display applications.glō's technology sidesteps the technical limitations of current planar LED technology. It allows for the creation of highly efficient, stable and ultimately unique red, green, blue (RGB) emitters out of one material system. It aims to achieve the industry’s best color stability and ultimately enables the growth of red, green and blue emitters on the same wafer. Highly-efficient white LEDs with high color rendering will be possible without the need for phosphor conversion. It is the next enabling technology for advanced display, illumination and automotive applications.glō nanowire light-emitting diodes (nLEDs) are based on its proprietary hetero-structured semiconductor nanowire epitaxial growth and process technologies for which standard manufacturing equipment and materials can be utilized.glō currently holds over 175 patents across US, Europe and Asia. These patents are not subject to any cross-licensing with the LED oligopoly. The glō team is constantly strengthening its intellectual property position in this technology and related applications.
- SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The company’s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the company’s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
- Sol Voltaics — Explore editorial solar guides, product analysis, comparisons and buying advice at SolVoltaics.com. Grab verified deals on Best Solar Brands.
Making Venture Happen. Televenture is one of the leading venture capital companies in Norway.
Show more...Investment focus
- Industry: Software, Manufacturing, Biotechnology
- Stage:Venture - Series Unknown, Seed
- Geography: Norway, United States
Investor stats
- Total investments: 26
- Round size: Venture - Series Unknown $686k–$5.9M
- Lead/follow: 65% lead, 35% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- CrayoNano — CrayoNano is a next generation semiconductor company. We specialize in nanotechnology that will enable a more sustainable and healthier life for tomorrow.
- Genetic Analysis — Genetic Analysis AS (GA) has the goal of being a leader within the field of molecular diagnostics of diseases related to gut imbalances. By utilizing the DNA-based GA-map™ array technology, profiles of a patient’s gut microbiota is quickly generated and can be related to various health conditions. Genetic Analysis has developed a DNA-basedtechnology platform that allows for simultaneous analysis of a large number of similarities (but not identical) gene fragments in one reaction. The company’s focus is to utilize this technology platform to identify variations in the hundreds of different bacteria that exist in the gut (large and small intestine). The GA - map makes it possible, for the first time, to offer a diagnostic solution – including early detection - for many diseases that are affected by imbalances in the gut microbiota. Genetic Analysis will offer kits and services for a wide range of applications.
- Stingray Marine Solutions — Stingray Marine Solutions is a Norwegian technology firm that produces a laser unit which, when lowered into salmon farming pens, kills sea lice. It is based on entrepreneur Esben Beck’s patented idea in 2010 for salmon louse removal using camera vision and laser. It all started with Esben Beck and a lathe in his basement in 1999. After more than10 years of deliveries to oil, gas and offshore companies, he decided to invest in his own products. He decided to found and develop his own salmon louse project, where design, production, software development, testing, and installation were carried out by using in-house resources.Stingray is based in Oslo, Norway.
Surveyor Capital is a fundamental equities business. Surveyor’s sector-aligned investment teams aim to generate alpha through a deep understanding of each company’s strategy, management teams, drivers of performance, and cyclical and secular industry trends over the medium and long term.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Post-IPO Equity, Series C
- Geography: United States, China, Canada
Investor stats
- Total investments: 170
- Round size: Series B $60M–$170M; Series C $60M–$226M; Post-IPO Equity $41M–$280M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Sol-Gel Technologies — Sol-Gel designs and delivers innovative dermatological drugs ranging from completely non-leachable to highly-controlled-release of unique formulations and compounds.
- Perspective Therapeutics — Perspective Therapeutics is dedicated to finding the best ways to deliver remedies to patients and their medical needs, and they believe in a targeted, individualized approach to cancer treatment. We design treatments that are given exactly where the doctor needs them.
Bioqube Ventures is a specialist life sciences venture capital fund investing in European biotech companies developing innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.Bioqube Venturesinvests through its independent fund “Bioqube Factory Fund I”: … an early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.… a fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.Medtech, healthtech and diagnostics are not part of our current investment scope.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Life Science
- Stage:Seed, Series A, Series B
- Geography: United States, France, Norway
Investor stats
- Total investments: 18
- Round size: Seed $5.7M–$24M; Series A $4M–$76M; Series B $23M–$108M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- Spica Therapeutics — Spica Therapeutics is a pioneering biotech company dedicated to transforming macrophage biology into breakthrough therapies for patients across multiple therapeutic areas. Leveraging its proprietary functional macrophage fingerprinting technology, Spica identifies and selectively targets disease-relevant macrophage sub
- Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
InnovationsKapital was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences, dynamic sectors that are rapidly expanding and whereNordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series C
- Geography: Sweden, Denmark, United States
Investor stats
- Total investments: 19
- Round size: Series B $5.6M–$30M; Series C $5.5M–$15M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Silecs — PiBond is an independent European maker of ultra-pure patterning, dielectric and optical materials for semiconductor, photonics and medical device clients.
- SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The company’s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the company’s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
- Action Pharma — Providing a surprisingly human shopping experience. Trusted and secure. Millions of domains to choose from.
Investment Company
Show more...Investment focus
- Industry: Software, Health Care, Life Science
- Stage:Pre-Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Aurora Analytica — Seven core decision engines and an orchestration layer working as one operating system for clinical development, from protocol optimization to study execution.
The Norwegian Research Council is the government's central research advisor. In 2012, the Research Council researched with more than 7 billion. This represents about 30% of R & D funding in the state budget.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Information Technology
- Stage:Grant, Seed, Venture - Series Unknown
- Geography: Norway, Sweden
Investor stats
- Total investments: 26
- Round size: Grant $90k–$1.6M; Venture - Series Unknown $1.7M–$25M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Borregaard — Borregaard operates one of the world's most advanced and sustainable biorefineries.
- Cartesian — Cartesian unlocks the power of thermal energy storage to help the world’s most energy-intensive sectors to boost energy efficiency and rapidly reduce their carbon footprint.
- Lace Lithography — Lace is building the patterning technology that will power the next 100 years of semiconductor manufacturing.
TD Veen is concerned with sustainable social development. Their contribution is to invest in companies and solutions that are good for both owners and society at large. The foundation of TD Veen is job satisfaction, creativity and a strong determination to invest in the very best people.At one stage they saw sense in targeting the investmentprofile, which also gave us a new perspective on the demand for returns and the role of investors. As a financial owner, they want to establish a healthy attitude toward results and returns. In companies where value is created over time.A differentiated portfolio is important to us. That is why they work with investments in new industries, such as e.g. health, or in parts of the world where they have not been before. Despite their Stavanger address, they want to invest outside of the petroleum sector.TD Veen has for many years supported the work of SOS Children’s Villages, including the project The Long Run, where they renovated old children’s villages in Romania and Lebanon. They have also contributed to starting up a separate pioneer project for foster families in Murmansk. Going ahead, they will to a greater degree also contribute to society at home, by building up a community of social entrepreneurs in Eiganesveien 95.
Show more...Investment focus
- Industry: Internet, Software, Information Technology
- Stage:Seed, Venture - Series Unknown
- Geography: Norway, United Kingdom, Germany
Investor stats
- Total investments: 24
- Round size: Seed $913k–$5.8M; Venture - Series Unknown $2M–$19M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Mobai — Provider of attack detection, image manipulation detection and authentication. Strong and successful research team on biometrics.
- Dagens — Together with farmers and chefs, we co-create a transparent and resilient food system for the future. The farmers get a bigger part of the profit. Buyers get easy access to unique, biodiverse produce at competitive prices.
- NoMy — Norwegian startup that researches and develops sustainable material and food solutions using mycelium
Gezina
Show more...Investment focus
- Industry: Health Care, Biotechnology, Clinical Trials
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The company’s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the company’s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United States, Sweden, France
Investor stats
- Total investments: 141
- Round size: Series A $6M–$73M; Series B $12M–$92M
- Lead/follow: 26% lead, 74% follow
- Last fund: Likely still investing — raised $179M in 2024
Portfolio highlights
- Neobiomics — Advancing neonatal care through evidence-based clinical nutrition.
- AMRA Medical — AMRA Medical is a digital health company transforming medical research and clinical care using rapid whole-body MRI technology.
- Ultragenyx Pharmaceutical — Ultragenyx is focused on developing first-ever approved treatments for rare and ultrarare diseases and moving the rare disease community forward.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Qomel Company is a healthcare and pharmaceutical services company that offers medical, diagnostic, and product distribution services. It operates ophthalmology, dental, wound care, and general medical services, while distributing pharmaceuticals and medical devices through warehouses and sales offices.
Show more...Investment focus
- Industry: Life Science, Biotechnology
- Stage:Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Kure Cells — Kure Cells delivers innovative solutions in cell therapy, biotechnology, and clinical research to advance modern healthcare.
Dynamk Capital is a New York headquartered growth equity and venture capital firm investing in life science industrials: tools, technologies and services that are critical for the discovery, development and production of life-saving therapies. Venture capital for Life Science tools.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, Canada, Norway
Investor stats
- Total investments: 20
- Lead/follow: no public data
Portfolio highlights
- CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
- Lucid Scientific — Lucid Scientific is the maker of Resipher - the world's first handheld cell culture monitor to measure real-time oxygen consumption from inside an incubator.
- Vernal Biosciences — Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.
Advent Venture Partners is one of Europe's most successful growth and venture capital investors in market-leading tech and life sciences businesses. They have designed their strategy, teams and funds so they can focus on backing a select few companies. They pride their selves on establishing true partnerships with entrepreneurs in order tobuild valuable businesses together.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series A
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 91
- Round size: Series A $6.6M–$26M; Series B $7M–$50M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $25M in 2019
Portfolio highlights
- Wiz — Organizations of all sizes and industries use Wiz to rapidly identify and remove the most critical risks in AWS, Azure, GCP, and Kubernetes so they can build faster and more securely.
- OpenCloud — Our cloud native software solutions dramatically improve operator business models and help quickly create new revenue-generating services.
- Acutus Medical — Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California.
Nordic Impact invests in, supports, and builds businesses and funds based around technology. The company's goal is to make impact investing mainstream and mobilize all business and capital towards solving the big problems in the world while making great financial returns.
Show more...Investment focus
- Industry: Chemical, Life Science, Visual Search
- Stage:Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Iris.ai — Powerful Tools for Your Research. We have built a world-leading AI engine for scientific text understanding. Applied to literature reviews, data extraction, post-market surveillance or any other task involving thousands of documents like papers or patents, this engine will make your life a whole lot easier.
Project Sandwater is a fresh take on venture investments within the Nordics and beyond.
Show more...Investment focus
- Industry: Medical, Consulting, Life Science
- Stage:Series A
- Geography: Norway, The Netherlands
Investor stats
- Total investments: 2
- Round size: Series A $12M–$20M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Delft IMP — Delft IMP (Intensified Materials Production) commercializes nanostructuring of particles using atomic and molecular layer deposition (ALD and MLD), based on the patented and publicized IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Following various feasibility projects betweenindustry and university, Delft IMP was initiated end 2014 to truly commercialize the technology.
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 203
- Round size: Series A $6M–$100M; Series B $15M–$114M; Series C $22M–$175M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely actively investing — fresh fund, raised $237M in 2025
Portfolio highlights
- CalciMedica — CalciMedica is a clinical-stage biopharmaceutical company advancing CRAC channel inhibitors for pulmonary hypertension and acute pancreatitis.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Korsana Biosciences — Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications.
Investment
Show more...Investment focus
- Industry: Software, Health Care, Life Science
- Stage:Pre-Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Aurora Analytica — Seven core decision engines and an orchestration layer working as one operating system for clinical development, from protocol optimization to study execution.
Patrick Pichette is based out of London, England, and is the Partner of Inovia Capital and also Board Member of Cohere. Patrick Pichette previously worked at Twitter as a Board of Directors. Patrick Pichette attended the University of Oxford.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, Germany, United States
Investor stats
- Total investments: 27
- Round size: Seed $913k–$10M; Series A $10M–$95M; Series B $15M–$95M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Mobai — Provider of attack detection, image manipulation detection and authentication. Strong and successful research team on biometrics.
- Kaedim — AI-powered 3D asset creation service delivering fast, production-ready 3D assets. Scale 3D pipelines without hiring, accelerate 3D game art production, and reduce 3D asset costs by up to 90%.
- Clove — Building a financial institution for how we live and work today.
World Wildlife Fund - The leading organization in wildlife conservation and endangered species. Learn how you can help WWF make a difference.
Show more...Investment focus
- Industry: Seafood, Aquaculture, Food Processing
- Stage:Seed, Series A
- Geography: Canada, Norway, Faroe Islands
Investor stats
- Total investments: 11
- Round size: Seed $1.5M–$4.7M; Series A $2.9M–$6.2M
- Lead/follow: 45% lead, 55% follow
Portfolio highlights
- SeaForester — Restoring the forgotten forests in our ocean.
- Cascadia Seaweed — Powered by the Sea. Proven on the Farm. Explore Cascadia Seaweed's portfolio of regenerative solutions, from kelp-based agricultural biostimulants to AI-powered biodiversity monitoring with OceanNexus. Through Cascadia Seaweed and Cascadia Nature-based Solutions, we're helping build healthier farms
- Ocean Rainforest — Ocean Rainforest offer a collection of premium fully-traceable seaweed products, mostly for food and cosmetic producers.The company has developed a structural system for macroalgae cultivation in open oceans and related on-shore processes for bringing the seaweed into a storage stable condition.
Protonic Partners is an investment firm.
Show more...Investment focus
- Industry: SaaS, Biometrics, Information Services
- Stage:Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Mobai — Provider of attack detection, image manipulation detection and authentication. Strong and successful research team on biometrics.
Biotechnology Investor funding in Norway at a glance
Stats across 128 deals from 152 investors.
Access all 152 investors in Norway Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology Investors in Norway investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 152 investors investing in Norway Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!